新诺威股价近期下跌，高管变动与战略合作引关注

Core Viewpoint - The company Xinnoway (300765.SZ) is currently facing significant stock price volatility due to poor performance forecasts and market sentiment, with a recent stock price of 35.79 yuan reflecting a 2.40% increase on the day but a 12.66% decline over the past 20 days [1]. Group 1: Stock Performance - As of February 10, 2026, Xinnoway's stock price was reported at 35.79 yuan, with a daily increase of 2.40% [1]. - The stock has experienced a cumulative decline of 3.82% over the past 5 days and 12.66% over the past 20 days [1]. - The current price-to-earnings ratio (TTM) is negative at -458.45, indicating the company is in a loss position [1]. Group 2: Institutional Insights - Southwest Securities reported on February 8, 2026, that the A-share innovative drug sector declined by 1.32%, with Xinnoway's weekly drop reaching 12.53%, placing it among the worst performers in the sector [1]. - The overall institutional rating is neutral, with profit forecasts indicating a net profit of 54 million yuan for 2025 (a 0.51% year-on-year increase) and an expected improvement to 73 million yuan in 2026 (a 35.19% year-on-year increase) [1]. - The uncertainty surrounding the innovative drug development process remains a significant risk factor [1]. Group 3: Recent Events - On January 30, 2026, Xinnoway completed a management adjustment, promoting the former board secretary Dai Long (a post-90s executive) to general manager, with Xu Wen taking over as board secretary [2]. - On the same day, the company announced a strategic cooperation with AstraZeneca, involving an upfront payment of 1.2 billion USD, with Giant Bio receiving 35% [2]. - The market reacted cautiously to the appointment of a young executive and the performance decline, resulting in a stock price drop of 15.72% on that day [2].